Merger with Oblikue Consulting gives specialist provider greater European and LATAM exposure for pricing and reimbursement
PharmaLex Group, a provider of specialized services for the pharma, biotech and medtech industries, has merged with Oblikue Consulting, a consultancy based in Spain.
Oblikue provides support to clients across all stages of the promotional process, from pre- to post-launch, and helps health authorities in defining healthcare policies to create market access and health economics and outcomes research (HEOR) programs for the pharma and biotech industries.
Per the merger, PharmaLex gains critical scale to its offering, when it comes to pricing and reimbursement (P&R), providing the chance for growth across Europe, the company notes. In addition, Oblikue has extensive knowledge in Latin American (LATAM) countries, with projects in Brazil and Chile.
“The acquisition of Oblikue fits with our objective to strengthen our health economics and market access expertise and expand our reach in Spain,” says Dr. Thomas Dobmeyer, CEO of PharmaLex. “Oblikue is well-known for its P&R experience, as well as its skill at liaising between pharma customers and healthcare stakeholders and tailoring projects to customer’s needs. We are very pleased to welcome them to PharmaLex.”